FDA Suspends Sensipar Trials Following Death Of Teenager

The U.S. Food and Drug Administration recently announced it has stopped all pediatric clinical trials of the drug Sensipar, following the death of a 14 year old patient who took part in one of the studies. Sensipar is a drug, developed by Amgen Inc, that reduces the levels of calcium in the blood by decreasing the release of parathyroid hormone (PTH) from the parathyroid gland. Having high levels of calcium can be the cause of a number of health problems, it has been associated with an increased risk of heart attack...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news

Related Links:

Publication date: Available online 1 April 2020Source: International Journal of Surgery Case ReportsAuthor(s): Paulo Cabrera, Carlos Roman, Silvia Barbosa, Fabian Alvarado, Esteban Diaz, Mayerlin Martinez
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Diabetes mellitus (DM) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular morbidity and mortality. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a new class of hypoglycemic agents that have shown significant promise in the reduction of cardiovascular events. Current guideline recommendations do not support the use of these agents in patients with CKD stage 3 or higher. We performed a comprehensive meta-analysis to evaluate their cardiovascular effects in patients with type 2 DM and CKD stage 3 or higher. A comprehensive search was performed in PubMed, Cochrane central, and Embase. S...
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
Each year 790,000 people in the United States suffer from a myocardial infarction. This results in the permanent loss of cardiomyocytes and an irreversible loss of cardiac function. Current therapies lower mortality rates, but do not address the core pathology, which opens a pathway to step-wise heart failure. Utilizing stem cells to regenerate the dead tissue is a potential method to reverse these devastating effects. Several clinical trials have already demonstrated the safety of stem cell therapy. In this review, we highlight clinical trials, which have utilized various stem cell lineages, and discuss areas for future research.
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
(Scripps Research Institute) A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows. A team led by John H. Griffin, PhD, a professor in the Department of Molecular Medicine at Scripps Research, made the unexpected finding after a series of experiments spanning three years and involving researchers from multiple collaborating institutions.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Heart attack symptoms include chest pain, difficulty breathing, and an overwhelming feeling of anxiety. But you could also be at risk of a deadly myocardial infarction and heart disease if you have painful lumps on your feet - do your toes look like this?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
ZOLL Medical, now a part of Asahi Kasei Group, won FDA approval for the latest version of its TherOx System. The product is designed to deliver SuperSaturated Oxygen (SSO2) therapy to limit heart muscle loss following “widowmaker” heart a...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Emergency Medicine Radiology Source Type: blogs
A new study assessed the prognosis of myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction with obstructive coronary artery disease.European Heart Journal
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Right ventricular dysfunction impacts the prognosis of various heart diseases. We set-out to examine which right ventricular functional parameters after STEMI and NSTEMI have prognostic value. Of 297 eligible ...
Source: BMC Research Notes - Category: Research Authors: Tags: Research note Source Type: research
Increased mean platelet volume (MPV) has been associated with elevated risk of stroke and myocardial infarction in the general population and stroke/pump thrombosis in Heartmate II recipients. It has been proposed that contact with foreign surfaces and centrifugation promote prothrombotic states with platelet activation and increased MPV. An association between MPV and outcomes of patients treated with percutaneous short-term circulatory devices has not been investigated.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (1029) Source Type: research
Acute coronary syndromes (ACS) are one of the most frequent conditions for admission to cardiology worldwide. Ethnic differences in the prevalence of cardiovascular risk factors,1,2 coronary atherosclerosis patterns,3-5 ischemic heart disease presentation,6,7 response to cardiovascular medications,8 and outcomes after myocardial infarction and revascularization9,10 have been reported between two of the world's largest ethnic groups: Asians and Whites. Little is known about the differences in the pathobiology of ACS between these two ethnic groups.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
More News: Calcium | Cardiology | Clinical Trials | Food and Drug Administration (FDA) | Health | Heart | Heart Attack | Hormones | Pediatrics | Sensipar | Study